prismCDX Implements Ultivue’s UltiMapper™ Platform for Standardized, Comprehensive Cancer Tissue Phenotypic Characterization

/in , /by

SEOUL, South Korea–prismCDX, a highly specialized contract research organization announced today the selection and adoption of the UltiMapper platform to broaden its offering of translational biomedical research services. The addition of Ultivue’s highly standardized multiplex tissue marker assays enables the identification of critical cellular phenotypes and tissue marker signatures in support of translational and clinical […]

Read more →

Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services

/in , /by

Kassel, Germany and Cambridge, MA – Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in multiplex tissue biomarker assays, to offer the biopharmaceutical industry new capabilities to improve the characterization of cancer patients’ samples selected for clinical research programs. UltiMapper multiplex immuno-histochemistry […]

Read more →

Genedata Expands Partnership with Boehringer Ingelheim to Digitalize Next Generation Cell Line Development

/in , , , /by

Genedata Selector® deployed to streamline complex cell line development processes Basel, Switzerland – Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced an expansion of its collaboration with Boehringer Ingelheim, a research-driven pharmaceutical company, to digitalize and automate complex cell line development processes. As part of this collaboration, Genedata Selector has been deployed […]

Read more →

Technology brings university scientists unparalleled potential for chemical, biological and human disease research First commercial research instrument of its kind in the world. MILFORD, Mass.–(BUSINESS WIRE)– Aston University and Waters Corporation (NYSE: WAT) announced today the completed installation of the world’s first Waters™ SELECT SERIES™ Cyclic™ IMS (ion mobility spectrometry) mass spectrometer within the University’s School of Health and Life Sciences, where the instrument will support research into the biology of human diseases, the discovery of new therapeutics and advances in biotechnology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191107005188/en/ Waters Corporation has completed the installation of the world’s first SELECT SERIES Cyclic IMS mass spectrometer within the School of Health Sciences at Aston University (Birmingham, England). (Photo: Business Wire) Waters Corporation has completed the installation of the world’s first SELECT SERIES Cyclic IMS mass spectrometer within the School of Health Sciences at Aston University (Birmingham, England). (Photo: Business Wire) Mass spectrometry (MS) is a widely deployed analytical method used by scientists to identify and quantify molecules in a sample and determine their detailed molecular structure. For example, it can be used to more effectively identify disease biomarkers that allow for early detection. Ion mobility spectrometry is a proven technique that separates ions by their size, shape and charge. The SELECT SERIES Cyclic IMS takes ion mobility to a new level, replacing the traditional linear ion mobility region with a novel compact cyclic device. Ions traverse around the cyclic region and with every pass greater ion mobility resolution is achieved. In addition, the advanced technology enables the unique ability to perform ion mobility selection for ion mobility/ion mobility and IMSn experiments. The new instrument will be used by researchers at Aston University and across the Midland Innovation consortium to answer complex biological questions. Andrew Pitt, Professor of Pharmaceutical Chemistry & Chemical Biology, Aston University said: “We are delighted to have this new technology in our lab here at Aston; it will provide us and other researchers in the Midlands with a step change in how we conduct our research. “The new instrument is one of a relatively recent class of mass spectrometers, incorporating ion mobility, which separate molecules based not only on their mass but also by their shape. This allows us to see what is going on in biology in much more detail, including information we are able to gain from the shape of molecules that will allow us to solve much more complex questions.” Combining novel IMS capability with significantly improved mass spectrometry performance and enabling software, this platform allows leading researchers to unlock the potential in scientific discovery. Jim Langridge, Advanced MS Technologies Waters Corporation said: “Human biology is extraordinarily complex and the SELECT SERIES Cyclic IMS gives research scientists the ability to probe deeper into the chemistry and biology of human disease like never before. “By collaborating with leading researchers like Professor Pitt, we continually advance the science of mass spectrometry, accelerating their research into human health and well-being.” Aston University scientists will run a visiting researcher programme that will allow researchers from many disciplines to visit Aston and work with the first-of-its-kind SELECT SERIES Cyclic IMS instrument, exploring its unparalleled experimental potential. The journal Analytical Chemistry documented the effectiveness and power of the cyclic IMS instrument in a recent article titled: A Cyclic Ion Mobility – Mass Spectrometry System. About Aston University Founded in 1895 and a University since 1966, Aston is a long established university led by its three main beneficiaries – students, business and the professions, and our region and society. Aston University is located in Birmingham and at the heart of a vibrant city and the campus houses all the university’s academic, social and accommodation facilities for our students. Professor Alec Cameron is the Vice Chancellor & Chief Executive. About Waters Corporation Waters Corporation (NYSE: WAT), the world’s leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With approximately 7,200 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. Waters and SELECT SERIES are trademarks of Waters Corporation.

/in , , , /by

Cambridge, UK – Abcam’s new engineered knockout cell lysates enable proteomic studies by providing researchers with “true negative” controls. Acquiring reliable off-the-shelf knockout mouse models or cell lines that match specific experimental requirements can be challenging, and often need to be sourced directly from individual researchers or labs. Abcam’s newly-launched collection addresses this issue by providing access to […]

Read more →

Cells that could lead to new therapies: PromoCell now offers in vitro disease models

/in , , , /by

Portfolio extension: Wide range of donor cells with common chronic diseases New models can help researchers investigate disease development and find new treatment approaches Matched growth media are optimized for pharmaceutical drug discovery Heidelberg, Germany – PromoCell, a premier manufacturer of human primary cells and cell culture products, now offers cell disease models covering a […]

Read more →

Mission Bio Launches Industry-First Single-cell Multi-omics Capabilities to Simultaneously Detect DNA and Protein from the Same Cell

/in , , , /by

As the first and only platform with these capabilities, the Tapestri Platform will enable key insights to drive the development of more impactful cancer therapies   SOUTH SAN FRANCISCO, Calif.  Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced its expansion into single-cell multi-omics. The company’s proprietary technology, the […]

Read more →

InSphero joins Science Exchange Network to Offer Expanded Online Access to 3D InSight™ Microtissue Technology and Services

/in , , , /by

PALO ALTO, Calif. & SCHLIEREN, Switzerland– R&D services platform will make it easier for researchers throughout the world to purchase InSphero assay ready models and services for drug efficacy and safety testing Science Exchange, the world’s leading SaaS-enabled marketplace for outsourced R&D, and InSphero AG today announced a collaboration to facilitate access to InSphero’s comprehensive portfolio of […]

Read more →

IONpath Announces Commercial Launch of MIBIscope™—the First Multiplexed Ion Beam Imaging System

/in , /by

MENLO PARK, Calif.– IONpath, Inc., a company revolutionizing multiplexed tissue imaging, launched the MIBIscope™ System, the first commercially available Multiplexed Ion Beam Imaging (MIBI™) system. The MIBIscope enables researchers to image over 40 biomarkers simultaneously at higher sensitivity, resolution, and throughput than existing methods. IONpath is showcasing the platform at the Society for Immunotherapy of Cancer […]

Read more →

Fluidigm Drives a New Standard in Human Immune Profiling

/in , , /by

More than 100 Academic, Pharmaceutical and Biotech Companies Select Maxpar Immune Profiling Panels Using CyTOF Technology to Accelerate Translational and Clinical Research SOUTH SAN FRANCISCO, Calif. — Fluidigm Corporation (NASDAQ:FLDM) today announced it has exceeded $1 million in revenue from its industry-leading Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Human Immune Monitoring Panel Kit. Used […]

Read more →